Atlas Discovery vs Isomorphic Labs

Side-by-side comparison of features, pricing, and ratings

Analysis reviewed Live tool data as of 2026-10-09
Cross-checked through our multi-step verification ·
Saved

At a glance

DimensionAtlas DiscoveryIsomorphic Labs
PricingContact-basedContact-based (pharma partnerships)
Core TechnologyExpressionVAE foundation models for patient drug response from clinical dataAlphaFold-based predictive & generative AI for protein-ligand interactions
Business ModelPartnerships, YC-backed, target pharma R&DDeep pharma collaborations (Novartis, J&J)
Target UserPharma scientists, trial designers, translational bioinformaticiansLarge pharma companies for drug discovery programs
Latest NewsExpressionVAE paper (Jun 2026), clinical prediction model (Jun 2026)Series B (Feb 2026), J&J collaboration (Jan 2026)

Isomorphic Labs is the pick for large pharma seeking end-to-end AI drug discovery with AlphaFold prestige and massive funding. Atlas Discovery is better for organizations focused on de-risking clinical trials via patient response predictions. Choose based on your bottleneck: molecule design or clinical success prediction.

Atlas Discovery
Atlas Discovery

AI-native pharma company building foundation models and agents that predict patient drug response and de-risk clinical trials

Visit Website
Isomorphic Labs
Isomorphic Labs

Isomorphic Labs applies generative AI drug discovery to design novel molecules and predict how candidates will perform.

Visit Website
Pricing
Contact Sales
Contact Sales
Plans
—
—
Popularity
5 views
7.5k views
Skill Level
Advanced
Advanced
API Available
Platforms
Web
—
Categories
🧬 Drug Discovery & Life Sciences
🧬 Drug Discovery & Life Sciences
Features
Foundation models predicting individual patient drug response from pre-clinical and clinical data
Ustekinumab response in ulcerative colitis predicted from baseline biopsy at AUROC 0.76
ExpressionVAE discrete-token encoding for single-cell data, 3–20x better than continuous baselines
scMDM masked discrete diffusion predicts treatment responders without response labels, 83.3% melanoma accuracy
Agent harness for drug repurposing that builds hypothesis-specific representations
Recovers dapagliflozin at rank 2 for heart failure vs TxGNN's 4,388th of 7,957
Agent-based clinical trial success prediction at AUROC 0.858, Phase III to approval
Virtual patient cohorts and power analysis for in silico trial design
Estimated UNIFI enrollment reduction of 458 patients via response prediction
ClinicBench benchmark forecasting next 30 days of care from 500k+ patient records
RepurposingBench with direct-probing held-out pairs and post-cutoff disclosures
Multi-omics integration linking patient biology to drug outcomes
Published research at ICLR '26, CSHL '26, and ICML '26
Partnered drug repurposing candidate in preclinical testing with Alliance to Cure CCM
Drug Design Engine spanning generative molecule design through lead optimization
Predictive AI models that anticipate how candidate drugs will perform
Generative models for designing novel molecules
Builds on and beyond the Nobel-winning AlphaFold system
End-to-end research collaborations from target identification to lead optimization
Digital biology approach aimed at discovery at digital speed
Named pharma partners include Johnson & Johnson, Novartis and Eli Lilly
Joined the Virtual Biology Initiative to build foundational data for AI disease models
Funder of Biohub's $1.8B initiative to train AI models that predict cell behavior
Bioresilience framework for biological threats and health emergencies
Series B investment round announced May 2026 to scale the Drug Design Engine
Follows a $600M external raise in March 2025
President Max Jaderberg appointed November 2025 to integrate AI and science
Interdisciplinary team of drug discovery experts and ML specialists
Founded by Demis Hassabis, who serves as CEO

Who should pick which

  • Large pharma company seeking AI-driven drug discovery
    Pick: Isomorphic Labs

    Isomorphic Labs offers a partnership model with AlphaFold-derived capabilities for protein-ligand interaction and molecular design, backed by $600M funding and collaborations with Novartis and J&J.

  • Clinical trial director aiming to reduce trial size and predict patient response
    Pick: Atlas Discovery

    Atlas Discovery's foundation models predict drug response from baseline biopsies (e.g., AUROC 0.76 for ustekinumab), enabling smarter trial design and power analysis.

  • Pharma startup wanting to rescue a failed compound
    Pick: Atlas Discovery

    Atlas Discovery includes drug rescue identification by modeling human clinical response, potentially repurposing compounds that failed in animal models.

  • Research institution exploring digital biology
    Pick: Isomorphic Labs

    Access to Isomorphic Labs' digital biology simulation at scale could accelerate basic research, though only through partner programs.

Frequently Asked Questions

Atlas Discovery vs Isomorphic Labs: which should you choose?

Isomorphic Labs is the pick for large pharma seeking end-to-end AI drug discovery with AlphaFold prestige and massive funding. Atlas Discovery is better for organizations focused on de-risking clinical trials via patient response predictions. Choose based on your bottleneck: molecule design or clinical success prediction.

What is the main difference between Isomorphic Labs and Atlas Discovery?

Isomorphic Labs focuses on early drug discovery (target identification, lead optimization) using AlphaFold AI. Atlas Discovery focuses on later-stage clinical trial success by predicting patient drug response from clinical data.

Can I use Isomorphic Labs as an individual researcher?

No. Isomorphic Labs operates exclusively through pharma partnerships, not offering standalone software or API access.

Does Atlas Discovery offer a self-service API?

No. Pricing is contact-based, and the platform is designed for R&D teams with clinical trial data access, not casual users.

Which company has more funding?

Isomorphic Labs raised $600M external investment in 2025 plus a Series B in 2026. Atlas Discovery is earlier stage (YC, Pear, Glasswing) with undisclosed amounts.

Which company uses AlphaFold?

Isomorphic Labs leverages the Nobel Prize-winning AlphaFold system from DeepMind as a core part of its Drug Design Engine.

What is ExpressionVAE?

Atlas Discovery's discrete-token encoding method for single-cell data, which outperforms continuous latent baselines by 3-20x on distributional metrics.

Has Atlas Discovery validated its model clinically?

Yes. It predicted response to ustekinumab in ulcerative colitis with an AUROC of 0.76 from baseline biopsies alone.

Is Isomorphic Labs a public company?

No. It is privately funded, backed by DeepMind/Google parent Alphabet and external investors.

More Atlas Discovery or Isomorphic Labs comparisons

Explore each tool further

Browse these categories

Still deciding? Get the weekly AI tools brief

One email a week — new tools, honest comparisons, no spam.

Last reviewed: July 3, 2026